82 related articles for article (PubMed ID: 8450476)
1. A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes.
Echizen H; Kawasaki H; Chiba K; Tani M; Ishizaki T
J Pharmacol Exp Ther; 1993 Mar; 264(3):1425-31. PubMed ID: 8450476
[TBL] [Abstract][Full Text] [Related]
2. Interspecies differences in enantioselective mono-N-dealkylation of disopyramide by human and mouse liver microsomes.
Echizen H; Mochizuki K; Tani M; Ishizaki T
J Pharmacol Exp Ther; 1994 Mar; 268(3):1518-25. PubMed ID: 8138963
[TBL] [Abstract][Full Text] [Related]
3. Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients.
Masuhara K; Ohno T; Hamaguchi K; Katoh K; Kashiwada K; Takahashi S; Tanaka Y; Someya K; Ogata H
Int J Clin Pharmacol Res; 1995; 15(3):103-13. PubMed ID: 8847151
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective disposition and metabolism of disopyramide in pediatric patients.
Echizen H; Takahashi H; Nakamura H; Ochiai K; Chiba K; Koike K; Ogata H; Ishizaki T
J Pharmacol Exp Ther; 1991 Dec; 259(3):953-60. PubMed ID: 1762088
[TBL] [Abstract][Full Text] [Related]
5. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals.
Jurima-Romet M; Crawford K; Cyr T; Inaba T
Drug Metab Dispos; 1994; 22(6):849-57. PubMed ID: 7895601
[TBL] [Abstract][Full Text] [Related]
6. Human pharmacokinetics and metabolism of disopyramide enantiomers.
Le Corre P; Gibassier D; Sado P; Le Verge R
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():233-7. PubMed ID: 1820885
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of cyclosporin A. II. Implication of the macrolide antibiotic inducible cytochrome P-450 3c from rabbit liver microsomes.
Bertault-Peres P; Bonfils C; Fabre G; Just S; Cano JP; Maurel P
Drug Metab Dispos; 1987; 15(3):391-8. PubMed ID: 2886317
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of cyclosporin A. III. Interaction of the macrolide antibiotic, erythromycin, using rabbit hepatocytes and microsomal fractions.
Fabre I; Fabre G; Maurel P; Bertault-Peres P; Cano JP
Drug Metab Dispos; 1988; 16(2):296-301. PubMed ID: 2898350
[TBL] [Abstract][Full Text] [Related]
9. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs.
Koyama E; Chiba K; Tani M; Ishizaki T
J Pharmacol Exp Ther; 1997 Jun; 281(3):1199-210. PubMed ID: 9190854
[TBL] [Abstract][Full Text] [Related]
10. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.
Ito K; Ogihara K; Kanamitsu S; Itoh T
Drug Metab Dispos; 2003 Jul; 31(7):945-54. PubMed ID: 12814973
[TBL] [Abstract][Full Text] [Related]
11. In vitro assessment of stereoselective hepatic metabolism of disopyramide in humans: comparison with in vivo data.
Le Corre P; Ratanasavanh D; Chevanne F; Gibassier D; Sado P; Le Verge R; Guillouzo A
Chirality; 1991; 3(5):405-11. PubMed ID: 1756095
[TBL] [Abstract][Full Text] [Related]
12. Microsomal oxidation of N,N-diethylformamide and its effect on P450-dependent monooxygenases in rat liver.
Amato G; Longo V; Mazzaccaro A; Gervasi PG
Chem Res Toxicol; 1996; 9(5):882-90. PubMed ID: 8828925
[TBL] [Abstract][Full Text] [Related]
13. [Stereoselectivity in N-dealkylation of disopyramide enantiomers in mouse hepatic microsomes].
Kiriyama A; Morita K; Shimakawa H; Yokoyama T
Yakugaku Zasshi; 1992 Jan; 112(1):61-4. PubMed ID: 1578345
[TBL] [Abstract][Full Text] [Related]
14. An in vitro study on the metabolism and possible drug interactions of rokitamycin, a macrolide antibiotic, using human liver microsomes.
Zhao XJ; Koyama E; Ishizaki T
Drug Metab Dispos; 1999 Jul; 27(7):776-85. PubMed ID: 10383920
[TBL] [Abstract][Full Text] [Related]
15. Effect of CYP3A inhibition on vesnarinone metabolism in humans.
Wandel C; Lang CC; Cowart DC; Girard AF; Bramer S; Flockhart DA; Wood AJ
Clin Pharmacol Ther; 1998 May; 63(5):506-11. PubMed ID: 9630823
[TBL] [Abstract][Full Text] [Related]
16. Effects of selective cytochrome P-450 inhibitors on the metabolism of thioridazine. In vitro studies.
Daniel WA; Syrek M; Haduch A
Pol J Pharmacol; 1999; 51(5):435-42. PubMed ID: 10817545
[TBL] [Abstract][Full Text] [Related]
17. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
Le Corre P; Gibassier D; Sado P; Le Verge R
Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences.
Greenblatt DJ; von Moltke LL; Harmatz JS; Counihan M; Graf JA; Durol AL; Mertzanis P; Duan SX; Wright CE; Shader RI
Clin Pharmacol Ther; 1998 Sep; 64(3):278-85. PubMed ID: 9757151
[TBL] [Abstract][Full Text] [Related]
19. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
20. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
Danie WA; Syrek M; Ryłko Z; Wójcikowski J
Pol J Pharmacol; 2001; 53(4):351-7. PubMed ID: 11990081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
